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Zinc is released into the synaptic cleft upon exocytotic stimuli, although the mechanism for 
its reuptake into neurons is unresolved. Here we show that the cellular prion protein enhances 
the uptake of zinc into neuronal cells. This prion-protein-mediated zinc influx requires the 
octapeptide repeats and amino-terminal polybasic region in the prion protein, but not its 
endocytosis. selective antagonists of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate 
(AmPA) receptors block the prion protein-mediated zinc uptake, and the prion protein 
co-immunoprecipitates with both GluA1 and GluA2 AmPA receptor subunits. Zinc-sensitive 
intracellular tyrosine phosphatase activity is decreased in cells expressing prion protein 
and increased in the brains of prion-protein-null mice, providing evidence of a physiological 
consequence of this process. Prion protein-mediated zinc uptake is ablated in cells expressing 
familial associated mutants of the protein and in prion-infected cells. These data suggest 
that alterations in the cellular prion protein-mediated zinc uptake may contribute to 
neurodegeneration in prion and other neurodegenerative diseases. 
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Zinc acts as a structural or catalytic component of a great number of proteins, and also functions as a neurotransmit-ter1. In addition, zinc modulates the function of glutamate 
and other neurotransmitter receptors2, and zinc is itself a signalling 
molecule directly regulating transcription factors3 and inhibiting 
protein tyrosine phosphatases4,5. In neurons, zinc is packaged into 
synaptic vesicles alongside glutamate, and both are released into the 
synaptic cleft upon exocytotic stimuli2,6–8. The synaptically released 
zinc is then taken up into the cytoplasm of postsynaptic neurons, 
although the molecular mechanisms involved are far from clear6. In 
non-neuronal cells, the uptake of zinc across the plasma membrane 
is mediated by members of the ZIP (Zrt/Irt-like protein) family of 
zinc transporters9, whereas in neurons zinc enters through activated 
voltage-gated Ca2 +  channels, Ca2 +  and zinc-permeable α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors, and 
ZIP-1 and ZIP-3 (refs. 6,10–12). The intracellular zinc concentra-
tion is controlled by these zinc importers, along with zinc exporters 
(members of the ZnT/SLC30 family of transporters, which trans-
port zinc from the cytosol to the lumen of intracellular organelles or 
out of the cell) and binding proteins such as metallothioneins6.
Prion diseases such as the Creutzfeldt–Jakob disease (CJD) in 
humans are characterised by the conformational conversion of the 
cellular prion protein (PrPC) into the protease-resistant, infectious 
form PrPSc that aggregates in the brain13. Although the accumulation 
of PrPSc is the main pathogenic event leading to neurodegeneration, 
loss of the normal function(s) of PrPC may also, in part, contrib-
ute to disease pathogenesis14,15. PrPC is a glycosyl-phosphatidyli-
nositol-anchored protein located on the surface of neurons, at both 
pre- and postsynaptic sites, throughout the central nervous system 
and is particularly abundant in the hippocampus, frontal cortex 
and striatum16. Within the amino terminal half of the PrPC are 
four complete copies of the octapeptide repeat (PHGG(G/S)WGQ), 
which can bind copper and zinc17–19. Both copper and zinc, but not 
a range of other divalent metal ions, stimulate the endocytosis of 
PrPC (refs 20,21), and deletion of, or mutations within, the octapep-
tide repeats abrogate this metal-dependent endocytosis20. Studies 
using peptides encompassing the full metal-binding octapeptide 
repeats anchored to the surface of lipid vesicles have demonstrated 
that both copper and, more so, zinc promote PrP–PrP interactions, 
leading to the suggestion that PrPC may be capable of responding to 
fluctuations in neuronal zinc levels22. Recently, it was reported that 
prion genes are evolutionary descendants of the ZIP family of trans-
membrane zinc transporters23, adding further to our earlier proposal 
that PrPC may have a role in sensing, scavenging or transporting zinc 
from the extracellular milieu24. However, whether PrPC is indeed 
involved in zinc uptake, the molecular mechanism involved and the 
relevance of this to brain zinc homeostasis and neurodegeneration 
has yet to be determined. In this study, using two zinc-selective fluo-
rescent dyes, Zinpyr-1 and Newport Green, we show for the first 
time that PrPC mediates the uptake of zinc into neuronal cells and 
that this uptake is mediated by AMPA receptors containing GluA1 
and lacking GluA2 subunits. Zinc uptake is disrupted when PrPC is 
mutated or when cells are infected with prion, which suggests that 
the reduction in uptake of zinc contributes to the neurodegeneration 
that is commonly associated with prion diseases.
Results
PrPC enhances neuronal zinc uptake. To investigate whether PrPC 
is involved in zinc uptake in neuronal cells, we exposed cells to 
zinc and measured the level of intracellular zinc using fluorescent 
dyes (Zinpyr-1 and Newport Green), which can be passively loaded 
into cells and used to detect intracellular-free (weakly bound, 
rapidly exchangeable) zinc. Untransfected SH-SY5Y cells, which 
do not endogenously express PrPC (Fig. 1a insert)20, accumulated 
zinc in a dose-dependent manner as measured with Zinpyr-1 
(Fig. 1a). However, SH-SY5Y cells stably expressing PrPC (Fig. 1a 
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Figure 1 | PrPC selectively facilitates zinc uptake. (a) untransfected sH-sY5Y cells (un; white bars) or sH-sY5Y cells expressing PrPC (blue bars)  
were exposed to Zn2 +  for 6 h and then stained with 10 µm Zinpyr-1. Kruskal–Wallis, **P < 0.01; ***P < 0.001. Insert: detection of PrPC in the un and  
PrPC-expressing cells with antibody 3F4, with actin as loading control. molecular weight markers in kDa. (b) Kinetic analysis of the relative increase in 
zinc uptake using newport Green in un sH-sY5Y cells (black symbols) compared with sH-sY5Y cells expressing PrPC (blue symbols), exposed for up 
to 30 min to 32 µm Zn2 +  (n = 3). Kruskal–Wallis, P < 0.05. The specificity of the Zinpyr-1 staining was determined by exposure of the cells expressing 
PrPC to (c) alternative divalent cations (100 µm) or the indicated combinations, or (d) specific cation chelators (1,10-phenanthroline (1,10 Phen) 160 µm; 
N,N,N′,N′-tetrakis (2-pyridylmethyl) ethylenediamine (TPEn) 16 µm; bathocuproine sulphonate (BCs) 16 µm). Data shown as mean ( ± s.e.m.). Zinpyr-1 
fluorescence corrected against DnA content (n = 8). Kruskal–Wallis, **P < 0.01.
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insert) showed a significantly enhanced level of zinc-associated 
fluorescence (Fig. 1a). SH-SY5Y cells expressing PrPC also had a 
significantly enhanced rate of zinc uptake as measured kinetically 
using Newport Green as compared with the untransfected cells 
(Fig. 1b). The specificity of the Zinpyr-1 fluorescence for zinc 
was determined by incubation of SH-SY5Y cells expressing PrPC 
with other divalent cations (Mn2 + , Fe2 + , Ca2 +  or Cu2 + ) before 
staining (Fig. 1c). Also, there was no competitive effect of either 
Cu2 +  or Mn2 +  when present in combination with zinc (Fig. 1c). 
Treatment with the zinc-specific chelators TPEN (N,N,N′,N′-tetrakis 
(2-pyridylmethyl)ethylenediamine) or 1,10-phenanthroline before 
Zinpyr-1 staining resulted in a significant decrease in zinc-associated 
fluorescence, whereas exposure of the cells to the copper chelator 
bathocuproine sulphonate did not alter the Zinpyr-1 fluorescence 
(Fig. 1d), confirming the specificity of the Zinpyr-1 staining for 
zinc. Under the conditions used, zinc (at 32 µM or 100 µM) had 
no detrimental effect on the viability of the SH-SY5Y cells at any 
time point as measured by Hoecsht 33342 staining (Supplementary 
Fig. S1a,b) and the Promega Live/Dead assay (data not shown).
To confirm a role for PrPC in enhancing zinc uptake in neuronal 
cells, both mouse N2a cells and rat primary hippocampal neurons 
were utilised in combination with small interfering RNA (siRNA) to 
knockdown endogenous PrPC and assess the effect of an acute loss of 
PrPC. Following siRNA treatment, there was a significant reduction 
(60 ± 2%) in the amount of PrPC that could be detected in the N2a 
cells (Fig. 2a insert), and zinc uptake was significantly suppressed as 
evaluated by both kinetic measurements (Fig. 2a) and fluorescence 
microscopy (Fig. 2c). In contrast, no alteration in zinc uptake was 
observed in the N2a cells treated with the non-targeting siRNA con-
trol (Fig. 2b). Immunofluorescence microscopy was used to validate 
the knockdown of PrPC in the hippocampal neurons (Fig. 2d). Zinc 
uptake was also reduced in hippocampal neurons treated with the 
PrPC-specific siRNA (Fig. 2e; Supplementary Fig. S2), but not in 
the neurons treated with the non-targeting siRNA control (Fig. 2f). 
Zinc (32 µM) did not decrease the viability of the N2a cells or the 
hippocampal neurons (Supplementary Fig. S1c).
To exclude the possibility that PrPC was enhancing retention 
of zinc within the cell rather than increasing its uptake, untrans-
fected SH-SY5Y cells and cells expressing PrPC were preloaded 
with zinc before the addition of Newport Green, and then the 
change in fluorescence was measured over time. As the zinc was 
transported out of the cells, there was a reduction in fluorescence 
over time; however, there was no difference in the rate by which 
the fluorescence changed between the untransfected and PrPC-
expressing cells (Fig. 2g). Fluorescence microscopy of permeabi-
lised cells revealed virtually no overlap in the distribution of PrPC 
and the Newport-Green staining for zinc (Fig. 2h). The punctuate 
staining for zinc reflects the way in which it is stored, as very little 
zinc exists free in the cytosol. Rather it is stored in at least three 
pools: tightly bound to a wide variety of proteins, bound to metal-
lothioneins or accumulated in the lumen of cytoplasmic vesicles and 
organelles27. These data, together with the fact that PrPC is located 
on the outer surface of the plasma membrane or in the lumen of 
the secretory pathway, whereas the Newport-Green staining for zinc 
is predominantly in the cytosol, indicates that PrPC is not acting 
to directly sequester zinc inside the cell. In contrast to PrPC, the 
sequence-related proteins Shadoo and Doppel did not enhance the 
uptake of zinc into the SH-SY5Y cells (Fig. 3a,b). Together, these 
data, using two different zinc-selective dyes and multiple cell sys-
tems, demonstrate for the first time that PrPC selectively enhances 
zinc uptake into neuronal cells.
The uptake of zinc does not require the endocytosis of PrPC. As 
zinc promotes the endocytosis of PrPC (ref. 20), we investigated 
whether the increase in intracellular zinc required the endocy-
tosis of the protein. The copper-mediated endocytosis of PrPC in 
SH-SY5Y cells is dependent on the transmembrane low-density 
lipoprotein receptor-related protein-1 (LRP1)28. First, to ascertain 
whether the zinc-mediated endocytosis of PrPC was also depend-
ent on LRP1, we used soluble receptor-associated protein (RAP) to 
inhibit the interaction between the two proteins and siRNA knock-
down of LRP1 in conjunction with the established endocytosis 
assay involving surface biotinylation and trypsin digestion28. Co-
incubation of the cells with RAP during the zinc incubation period 
significantly inhibited the endocytosis of PrPC, as did the siRNA-
mediated knockdown of LRP1 before the addition of zinc (Fig. 
4a and b), indicating that the zinc-mediated endocytosis of PrPC 
is also dependent on LRP1. However, blocking the endocytosis of 
PrPC either by siRNA knockdown of LRP1 (Fig. 4c) or with RAP 
(Fig. 4d) did not reduce the uptake of zinc into the cells, indicating 
that the endocytosis of PrPC is not the mechanism responsible for 
the enhanced uptake of zinc. Interestingly, both RAP and siRNA 
knockdown of LRP1 caused a small but significant increase in the 
uptake of zinc (Fig. 4c and d). It is possible that blocking the endo-
cytosis of PrPC would cause more PrPC to be available at the cell 
surface to facilitate zinc uptake.
The PrPC-enhanced zinc uptake is mediated by AMPA receptors. 
Having excluded PrPC endocytosis as the mechanism behind the 
enhanced uptake of zinc, we investigated alternative routes by 
which zinc may be entering the cells. It has been shown previously 
that zinc can enter neurons through AMPA receptors10. To investi-
gate whether AMPA receptors were involved in the PrPC-mediated 
zinc uptake, the SH-SY5Y cells were incubated with CNQX, a com-
petitive AMPA/kainate receptor antagonist. CNQX significantly 
reduced the uptake of zinc in the cells expressing PrPC (Fig. 5a), 
but had no effect on the uptake of zinc in the untransfected cells 
(Fig. 5b). The ability of CNQX to reduce the PrPC-enhanced uptake 
of zinc was confirmed by immunofluorescence microscopy of the 
cells following exposure to Newport Green (Fig. 5c). CNQX also 
significantly reduced the uptake of zinc into the hippocampal 
neurons to a level similar to that observed following knockdown of 
PrPC expression by siRNA (Fig. 5d). Indeed, when the two treat-
ments were combined, addition of CNQX did not further decrease 
zinc uptake beyond that observed for the siRNA knockdown of 
PrPC (Fig. 5e). We also explored the effect of direct activation of 
AMPA receptors on zinc uptake. The siRNA knockdown of PrPC 
in the hippocampal neurons ablated the AMPA-mediated increase 
in zinc uptake (Fig. 5f). Together, these data suggest that the 
PrPC-enhanced zinc uptake is mediated by AMPA receptors.
Mechanism of PrPC-mediated zinc uptake via AMPA receptors. 
To characterise further the role of AMPA receptors in the PrPC-
enhanced zinc uptake, the Newport-Green fluorescence was meas-
ured in the SH-SY5Y cells expressing PrPC and in the hippocampal 
neurons exposed to either IEM-1460 or pentobarbital, which inhibit 
GluA2-lacking or GluA2-containing AMPA receptors, respectively. 
Surprisingly, both IEM-1460 (Fig. 6a,b) and pentobarbital (Fig. 6c,d) 
diminished the PrPC-mediated zinc uptake. Previously, PrPC has 
been shown to interact with the GluA2 subunit of AMPA recep-
tors29. To confirm this observation and to determine whether PrPC 
also interacts with the GluA1 subunit, immunoprecipitation from 
mouse brain homogenate using antibodies against PrPC, GluA1 
and GluA2 was performed and the resulting immunoprecipi-
tates western blotted with antibodies against each protein. Both 
GluA1 and GluA2 co-immunoprecipitated with PrPC, and PrPC  
co-immunoprecipitated with both GluA1 and GluA2 (Fig. 6e). 
No co-immunoprecipitation was observed using Sepharose beads 
only, or with beads coated with a non-specific IgG (Fig. 6e) or using 
brain homogenate from a PrP-null mouse (Fig. 6f). In addition, 
PrPC increased the cell surface expression of the GluA1 subunit 
(Fig. 6g,h).
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To explore further the molecular mechanism underlying the 
PrPC-mediated zinc uptake via AMPA receptors, we determined 
the regions of PrPC involved in (i) the uptake of zinc and (ii) the 
interaction with AMPA receptors. Cells expressing wild-type PrPC 
were incubated with epitope-specific antibodies before exposure 
to zinc. Incubation of the cells with antibody SAF32, which recog-
nises an epitope encompassing amino acids 59–89 contained within 
the octapeptide repeat region, significantly reduced the uptake of 
zinc (Fig. 7a), whereas incubation of the cells with antibody 8H4, 
which recognises residues 175–185, had no effect on the PrPC-
mediated increase in zinc uptake (Fig. 7a). Incubation of the cells 
with a non-specific antibody (against the transferrin receptor) had 
no effect on the uptake of zinc (Fig. 7a). Antibody SAF32, but not 
the transferrin-receptor antibody, also significantly reduced the 
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Figure 2 | PrPC facilitates zinc uptake into neurons. Zinc uptake measured using newport Green in n2a cells exposed for up to 30 min to (a) 32 µm 
Zn2 +  (blue symbols) or to 32 µm Zn2 +  following knockdown of PrPC with siRnA (green symbols; Kruskal–Wallis, P < 0.05) or to (b) 32 µm Zn2 +  (blue 
symbols) or 32 µm Zn2 +  with non-targeting siRnA control (green symbols; n = 6). Insert in a: expression of PrPC in untreated, PrPC-specific siRnA or  
non-targeting siRnA-treated n2a cells, with actin as loading control. (c) Zinc uptake visualised by fluorescence microscopy using newport Green in  
n2a cells exposed to 100 µm Zn2 +  (Zn) or to 100 µm Zn2 +  following knockdown of PrPC expression with siRnA (Zn + siRnA). scale bars equal 10 µm.  
(d) Fluorescence images of primary hippocampal neurons showing the distribution of PrPC (probed with antibody 6H4) in untreated, PrPC-specific  
siRnA-treated or non-targeting siRnA-treated cells. scale bar equals 10 µm (n = 10). Zinc uptake measured using newport Green in rat primary 
hippocampal neurons exposed for up to 30 min to (e) 32 µm Zn2 +  (blue symbols) or to 32 µm Zn2 +  following knockdown of PrPC expression with  
siRnA (green symbols; Kruskal–Wallis, P < 0.05) or to (f) 32 µm Zn2 +  (blue symbols) or 32 µm Zn2 +  with non-targeting siRnA control (green symbols; 
n = 3). Data shown as the relative newport Green fluorescence corrected against DnA content and plotted as mean ± s.e.m. (g) untransfected sH-sY5Y 
cells (dotted line) or sH-sY5Y cells expressing PrPC (solid line) were pre-loaded with 32 µm Zn, followed by 5 µm newport Green for a further 30 min,  
to label the intracellular Zn. The change in fluorescence with time was measured on addition of fresh medium to determine whether PrPC promoted 
retention of Zn. (h) Cellular localisation of newport Green fluorescence (green) and PrPC (red) in sH-sY5Y cells expressing PrPC exposed to 32 µm Zn. 
scale bars equal 5 µm.
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uptake of zinc in the hippocampal neurons (Fig. 7b). To explore 
further the role of the metal-binding octapeptide repeats of PrPC 
in the uptake of zinc, we utilised cells expressing PrP∆Oct, in 
which the octapeptide repeat sequence has been removed20. The 
Zinpyr-1 fluorescence in the SH-SY5Y cells expressing PrP∆Oct 
(Fig. 7c insert) following exposure to zinc was similar to that of 
the untransfected cells (Fig. 7c). Next, we investigated whether the 
octapeptide repeats were required for the interaction with AMPA 
receptors. PrP∆Oct still co-immunoprecipitated with the GluA2 
subunit (Fig. 7d), and wild-type PrPC co-immunoprecipiated 
with both GluA1 and GluA2 following chelation of zinc (Fig. 7e). 
To explore further the region of PrPC involved in the interaction 
with the AMPA receptor, we utilised a construct of PrPC, PrP∆N, 
which lacks the four amino acids (lysyl-lysyl-arginyl-proline) from 
the N terminus of the mature protein30. PrP∆N is trafficked to the 
cell surface, localised to detergent-resistant lipid rafts and under-
goes endoproteolytic cleavage to generate the C1 fragment similarly 
to wild-type PrPC (refs 30–32). However, PrP∆N failed to enhance 
the uptake of zinc into cells (Fig. 7c) and also failed to co- 
immunoprecipitate with the GluA2 subunit (Fig. 7d). These data 
indicate that the metal-binding octapeptide repeats in PrPC are 
required for the enhanced zinc uptake but not for the interaction 
with the AMPA receptor, whereas the N-terminal polybasic region 
of the protein is critical for the interaction with the AMPA receptor.
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Figure 4 | Zinc uptake does not require the endocytosis of PrPC. (a) sH-sY5Y cells expressing PrPC were surface biotinylated and then either left 
untreated, exposed to 20 µg ml − 1 RAP or 2 µm LRP1 siRnA in the presence or absence of 100 µm Zn2 + . Before lysis, cell-surface PrPC was removed 
by trypsin digestion. PrPC was immunoprecipitated from the cell lysates with antibody 3F4 and analysed by western blot with the biotin-labelled PrPC 
detected with peroxidase-conjugated streptavidin. (b) Quantification of the inhibitory effect of RAP and LRP1 siRnA treatment on the amount of zinc-
stimulated endocytosis across multiple immunoblots from three separate experiments. Kruskal–Wallis, ***P < 0.001. (c) Zinc uptake measured using 
newport Green in sH-sY5Y cells expressing PrPC exposed to 100 µm Zn2 +  (blue symbols) or to 100 µm Zn2 +  following knockdown of LRP1 expression 
with siRnA (green symbols). Kruskal–Wallis, P < 0.05. (d) Zinc uptake measured using newport Green in sH-sY5Y cells expressing PrPC exposed to 
100 µm Zn2 +  (blue symbols) or to 100 µm Zn2 +  in the presence of 20 µg ml − 1 RAP (green symbols). Kruskal–Wallis, P < 0.05. Data shown as the relative 
newport Green fluorescence corrected against DnA content and plotted as mean ± s.e.m. (n = 3).
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Tyrosine phosphatase activity is increased in PrPC-null mice. 
Intracellular protein tyrosine phosphatase activity is exquisitely 
sensitive to zinc4,5. Therefore, to determine whether the increased 
uptake of zinc observed in cells expressing PrPC affected a cel-
lular event, we measured the tyrosine phosphatase activity in the 
cells. In agreement with previous reports4,5, zinc directly inhib-
ited phosphatase activity when added to the SH-SY5Y cell lysate 
(Supplementary Fig. S3). In the cells expressing PrPC, there was a 
significant reduction of phosphatase activity as compared with the 
untransfected cells (Fig. 8a), indicating that the enhanced uptake 
of zinc by PrPC has a downstream effect on a cellular process. To 
confirm that PrPC disrupted zinc homeostasis in vivo, we measured 
the tyrosine phosphatase activity in the brains of wild-type and 
PrPC-null mice. Consistent with a role for PrPC in neuronal zinc 
uptake, there was a higher level of tyrosine phosphatase activity 
in the brains of the PrPC-null mice compared with the wild-type, 
age-matched control mice (Fig. 8b). These data, for the first time, 
indicate that PrPC is involved in the physiological homeostasis of 
neuronal zinc.
Enhanced uptake of zinc is lost in prion disease. As zinc is reduced 
in the brain in prion disease33,34, and there is debate whether prion 
diseases involve a loss of a normal function of PrPC in addition to the 
toxic gain-of-function14,15, we investigated the effect of a number of 
prion disease-associated mutations in PrPC on zinc uptake. PG14 has 
an additional nine octapeptide repeats and results in familial CJD35, 
whereas A116V and P101L are both single point mutations, which 
cause the Gerstmann–Straussler–Scheinker syndrome (GSS)36,37. 
D177N with valine at position 128 (D177N/V128) also results in 
GSS, whereas with methionine at position 128 (D177N/M128) 
causes familial fatal insomnia38. All mutants were stably expressed 
in SH-SY5Y cells to similar levels (Fig. 8c insert). In contrast to 
wild-type PrPC, none of the five disease-associated mutants of PrPC 
enhanced zinc uptake above that seen in the untransfected cells 
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Figure 5 | PrPC-enhanced zinc uptake requires AMPA receptors. Zinc uptake measured using newport Green in (a) sH-sY5Y cells expressing PrPC  
or in (b) untransfected sH-sY5Y cells exposed to 32 µm Zn2 +  (blue symbols) or to 32 µm Zn2 +  and 10 µm CnQX (green symbols). Kruskal–Wallis, 
P < 0.05 in a. (c) Zinc uptake visualised using newport Green in sH-sY5Y cells expressing PrPC exposed to 32 µm Zn2 +  or to 32 µm Zn2 +  in the presence 
of 10 µm CnQX. scale bars equal 10 µm. (d) Zinc uptake measured using newport Green in rat primary hippocampal neurons exposed to 32 µm Zn2 +  
(blue symbols), to 32 µm Zn2 +  and 10 µm CnQX (green symbols), or to 32 µm Zn2 +  following knockdown of PrPC expression with siRnA (red symbols). 
(e) Zinc uptake measured using newport Green in rat primary hippocampal neurons exposed to 32 µm Zn2 +  (blue symbols) or to 32 µm Zn2 +  following 
knockdown of PrPC expression with siRnA (green symbols), or 32 µm Zn2 +  and 10 µm CnQX following knockdown of PrPC expression with siRnA  
(red symbols). (f) Zinc uptake measured using newport Green in rat primary hippocampal neurons exposed to 32 µm Zn2 +  in the presence of 100 µm 
AmPA (green symbols) following knockdown of PrPC expression with siRnA (red symbols), or to 100 µm AmPA following knockdown of PrPC  
expression with siRnA (purple symbols). Data shown as the relative newport Green fluorescence corrected against DnA content and plotted as  
mean ± s.e.m. (n = 3).
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(Fig. 8c). To investigate the mechanism underlying the lack of zinc 
uptake in the disease-associated mutants of PrPC, we determined 
whether they co-immunoprecipitated with the AMPA receptor. 
Neither of the D177N mutants nor P101L interacted with the 
GluA1 or GluA2 subunits (Fig. 8d), indicating that in these disease- 
associated mutants of PrPC the mechanism underlying the inability 
to enhance zinc uptake may be due to loss of the interaction with 
AMPA receptors. Although the PG14 and A116V mutants still 
co-immunoprecipitated with the GluA2 subunit, in the cells express-
ing these two mutants we observed that the level of the GluA1 subu-
nit was significantly reduced (Fig. 8d and Supplementary Fig. S4), 
suggesting that this likely underlies the inability of the PG14 and 
A116V mutants to increase zinc uptake. Finally, to determine 
whether zinc uptake was affected upon the conformational con-
version of PrPC to PrPSc, zinc uptake was measured in persistently 
scrapie-infected ScN2a cells. Although a significant increase in zinc 
uptake was measured in uninfected N2a cells following exposure to 
exogenous zinc (Fig. 8e), no such increase was measured in the 
c d
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Figure 6 | PrPC interacts with AMPA receptor subunits. Zinc uptake measured using newport Green in sH-sY5Y cells expressing PrPC (a,c) and in  
rat primary hippocampal neurons (b,d) exposed to 32 µm Zn2 +  (blue symbols) or to 32 µm Zn2 + , and (a,b) 10 µm IEm-1460 (green symbols) or  
(c,d) 100 µm pentobarbital (green symbols). Data shown as the relative newport Green fluorescence corrected against DnA content and plotted as 
mean ± s.e.m. (n = 3). Kruskal–Wallis, P < 0.05. Co-immunoprecipitation from (e) wild-type 129/P2 or (f) PrP − / −  129/P2 mouse brain using antibodies 
against PrPC (6H4), GluA1, GluA2, control rabbit anti-mouse IgG or no antibody for the bead-only control, and then probed with antibodies against  
PrPC (sAF32), GluA1 or GluA2 as indicated. (g) Cell lysates from either untransfected (un) sH-sY5Y cells or those expressing PrPC were analysed  
for their expression of PrPC and GluA1. Actin was included as a loading control. Cell monolayers were treated with cell-impermeant biotin to determine 
the amount of GluA1 at the cell surface. GluA1 was immunoprecipitated from the lysates and the biotin-labelled GluA1 detected using peroxidase-
conjugated streptavidin. (h) Cell surface GluA1 was quantified from multiple immunoblots (n = 3). Kruskal–Wallis, *P < 0.05.
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scrapie-infected ScN2a cells (Fig. 8f). These data indicate that the 
PrPC-mediated zinc uptake is lost in cells expressing prion disease-
associated mutants of PrPC and upon conversion of PrPC to PrPSc.
Discussion
Zinc can bind to the octapeptide repeats in PrPC (refs 18,19,22) and 
promote its endocytosis20,21; however, the role of PrPC in cellular 
zinc metabolism has remained enigmatic. For the first time, by uti-
lising zinc-specific fluorescent dyes, we have shown that PrPC via 
AMPA receptors directly influences the zinc content of neuronal 
cells. We have also shown that the role of PrPC in neuronal zinc 
homeostasis is of functional relevance, as evidenced by the increase 
in intracellular zinc-sensitive protein tyrosine phosphatase activity 
in the brains of PrPC-null mice. Our observations are consistent with, 
and provide the first mechanistic explanation for, the recent reports 
of reduced zinc in the hippocampus and other brain regions of 
PrPC-null mice39 and of altered levels of zinc in specific brain regions 
of PrPC transgenic mice39. Our data suggest that PrPC may provide 
neuroprotection by facilitating the reuptake of the potentially neu-
rotoxic synaptic zinc released upon glutamatergic neurotransmis-
sion. Furthermore, by reduction of protein tyrosine phosphatase 
activity, this PrPC-mediated increase in intracellular zinc may affect 
learning and memory40, and promote neuronal survival41.
Our data show that PrPC enhances zinc uptake through AMPA 
receptors, which are known to have a key role in zinc homeostasis 
in neurons6. AMPA receptors are composed of various combina-
tions of four subunits (GluA1–GluA4) and are widely expressed 
in neurons throughout the central nervous system. In the hippoc-
ampus and cerebral cortex, the predominantly expressed subunits 
are GluA1 and GluA2, with low levels of GluA3 and GluA442. 
The receptor displays high Ca2 +  and zinc permeability in the 
absence of the GluA2 subunit and low Ca2 +  and zinc permeability 
in the presence of this subunit2. Although receptors containing the 
GluA2 subunit are the most sensitive to pentobarbital, non-GluA2- 
containing receptors also display measurable sensitivity to this 
drug43. Therefore, we cannot rule out the possibility that, although 
we used a concentration of pentobarbital that should display 
minimal effect on GluA2-lacking AMPA receptors, there was 
some inhibition of the Ca2 + /zinc-permeable GluA2-lacking 
receptors. The antagonist data, along with the co-immunoprecipita-
tion data, clearly indicates that GluA2-lacking, GluA1-containing 
AMPA receptors are involved in the PrPC-mediated zinc uptake. 
One possible molecular mechanism underlying this effect is that 
PrPC stabilises the AMPA receptor in a zinc transport-competent 
location at the cell surface as evidenced by the increased surface 
expression of the GluA1 subunit in the presence of PrPC.
Through the use of site-specific antibodies and a deletion con-
struct, we show that the octapeptide repeats in PrPC are required for 
the zinc uptake. There is evidence that the four octapeptide repeats 
bind a single zinc ion with a Kd of 200 µM, indicating that zinc 
binding to PrPC is possible at the reported synaptic zinc concentra-
tions of up to 300 µM18,44. It is thus possible that zinc binds to the 
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Figure 7 | The N terminus of PrPC is required for the interaction with AMPA subunits. (a) Zinc uptake measured using newport Green in sH-sY5Y 
cells expressing wild-type PrPC exposed to 32 µm Zn2 +  (blue symbols), 32 µm Zn2 +  and 10 µg ml − 1 antibody sAF32 (green symbols), 32 µm Zn2 +  and 
10 µg ml − 1 antibody 8H4 (red symbols) or 32 µm Zn2 +  and 10 µg ml − 1 anti-transferrin receptor antibody (purple symbols). (b) Zinc uptake measured 
using newport Green in rat primary hippocampal neurons exposed to 32 µm Zn2 +  (blue symbols), 32 µm Zn2 +  and 10 µg ml − 1 antibody sAF32 (green 
symbols) or 32 µm Zn2 +  and 10 µg ml − 1 anti-transferrin receptor antibody (red symbols). Data shown as the relative newport Green fluorescence 
corrected against DnA content and are plotted as mean ± s.e.m. (n = 3). Kruskal–Wallis, P < 0.05 for sAF32 compared with no antibody. (c) untransfected 
(un) sH-sY5Y cells or sH-sY5Y cells expressing either wild-type PrPC, PrP∆oct or PrP∆n were exposed to 100 µm Zn2 +  and stained using 10 µm Zinpyr-
1. Data shown as mean ( ± s.e.m.). Zinpyr-1 fluorescence corrected against DnA content (n = 8). Insert shows expression of wild-type PrPC, PrP∆oct and 
PrP∆n with actin as a loading control. molecular weight markers in kDa. (d) Co-immunoprecipitation from lysates of sH-sY5Y cells expressing PrP∆oct 
or PrP∆n using antibodies against PrPC (6H4), GluA2, control rabbit anti-mouse IgG or no antibody for the bead-only control, and then probed with 
antibodies against PrPC (6D11 for PrP∆oct or sAF32 for PrP∆n) or GluA2 as indicated. (e) Co-immunoprecipitation from wild-type ola/P2 mouse brain 
using antibodies against PrPC (6H4), GluA1, GluA2, control rabbit anti-mouse IgG or no antibody for the bead-only control with 20 µm TPEn included  
in all buffers and washes. samples were probed with antibodies against PrPC (sAF32), GluA1 or GluA2 as indicated.
ARTICLE 

nATuRE CommunICATIons | DoI: 10.1038/ncomms2135
nATuRE CommunICATIons | 3:1134 | DoI: 10.1038/ncomms2135 | www.nature.com/naturecommunications
© 2012 Macmillan Publishers Limited. All rights reserved.
octapeptide repeats with relatively low affinity, and then channels 
the metal to the AMPA receptor for transport across the membrane. 
The recent report that PrPC may be evolutionarily related to the ZIP 
family of zinc transporters23 would support such a mechanism by 
which PrPC and AMPA receptors together facilitate zinc uptake. 
In the ZIP proteins, which have zinc-binding histidine-contain-
ing motifs in their extracellular N-terminal repeat sequences and a 
carboxy-terminal multiple-membrane-spanning domain, the zinc 
sensor/scavenger and membrane-transport functions are combined 
in the single protein; whereas in the case of PrPC and AMPA recep-
tors, these two functions reside in different proteins. The octapeptide 
repeats in the glycosyl-phosphatidylinositol-anchored PrPC act as a 
zinc sensor/scavenger, and then transfers the metal to the transmem-
brane AMPA receptor for transport across the plasma membrane.
Although the octapeptide repeats are required for the PrPC-
mediated zinc uptake, they are not involved in the interaction with 
the AMPA receptor as shown by the ability of the PrP∆Oct mutant 
to co-immunoprecipiate with the AMPA receptor subunits and 
the inability of zinc chelation to disrupt the PrPC-AMPA receptor 
interaction. However, the N-terminal polybasic region of PrPC is 
required for mediating the interaction with the AMPA receptor. 
Loss of this interaction between the two proteins appears to be criti-
cal for the PrPC-enhanced zinc uptake, as evidenced with the PrP∆N 
mutant and with the disease-associated mutants P101L and D177N, 
which all failed to co-immunoprecipitate with the AMPA receptor 
and to enhance zinc uptake. The N-terminal polybasic residues that 
are missing from the PrP∆N mutant have been implicated in several 
biological functions of PrPC, including endocytic trafficking and 
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Figure 8 | Protein tyrosine phosphatase activity is enhanced in PrPC-null mice and zinc uptake is reduced in prion disease. (a) Lysates from 
untransfected sH-sY5Y cells (un) or cells expressing PrPC were incubated with phosphopeptide for 45 min at 37 °C to measure tyrosine phosphatase 
activity. Data shown as mean ( ± s.e.m.) (n = 3). Independent student’s t-test, **P < 0.01. (b) Tyrosine phosphatase activity was measured in whole-brain 
homogenate from wild-type 129/P2 (WT) or 129/P2 PrP − / −  mice. Data shown as mean ( ± s.e.m.; n = 8). Independent student’s t-test, *P < 0.05.  
(c) sH-sY5Y cells expressing the various disease-associated mutants of PrPC were exposed to 100 µm Zn2 +  and stained using 10 µm Zinpyr-1. Data 
shown as mean ( ± s.e.m.). Zinpyr-1 fluorescence corrected against DnA content (n = 8). Kruskal–Wallis, **P < 0.01. Insert shows expression of the  
various disease-associated mutants of PrPC. Lane 1, wild-type PrPC; lane 2, PG14; lane 3, A116V; lane 4, P101L; lane 5, D177n/m128; and lane 6,  
D117n/V128. molecular weight marker in kDa. (d) Co-immunoprecipitation from P101 L, D177n (m128), D177n (V128) mouse brain or sH-sY5Y  
cell lysates expressing PG14 or A116V using antibodies against PrPC (6H4), control rabbit anti-mouse IgG or no antibody for the bead-only control, and 
then probed with antibodies against PrPC (sAF32), GluA1 or GluA2 as indicated. Zinc uptake measured using newport Green in (e) uninfected n2a cells 
and (f) scrapie-infected scn2a cells, either not supplemented with Zn2 +  (light blue symbols) or supplemented with 32 µm Zn2 +  (dark blue symbols). 
Data shown as the relative newport Green fluorescence corrected against DnA content and plotted as mean ± s.e.m. (n = 3). Kruskal–Wallis, P < 0.05  
in the uninfected cells.
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localisation to clathrin-coated pits30, binding of glycosaminogly-
cans31,45,46, inhibition of the β-secretase cleavage of the amyloid 
precursor protein31, binding of the amyloid-β peptide47 and in 
mediating PrPC-related neurotoxicity48.
There is discussion as to whether prion diseases are solely due 
to the gain of toxic function on formation of PrPSc or whether loss 
of the normal function(s) of PrPC may also contribute to disease 
pathogenesis14,15. Our observations that zinc uptake is lost in cells 
expressing mutated forms of PrPC associated with the human prion 
diseases CJD, GSS and familial fatal insomnia, and in persistently 
scrapie-infected cells, lend support to the latter hypothesis. Con-
sistent with this observed reduction in zinc uptake in the scrapie-
infected cells, the zinc content of brains from scrapie-infected mice 
was reduced by >70%34, and in the frontal cortex of sporadic CJD 
cases the zinc content was decreased compared with controls33, 
providing additional evidence that upon conversion to PrPSc  
neuronal uptake of zinc may be compromised. It has been sug-
gested that some features of the neurological illness associated with 
inherited PrPC mutations may be attributable to a loss of PrPC 
neuroprotective function49. In this context, it is interesting to 
note that the PG14 mutant associated with familial CJD35, which 
had impaired neuroprotective activity in transgenic mice50, was 
ineffective in enhancing zinc uptake.
The role we have described here for PrPC in mediating neuronal 
zinc uptake may also impact on another neurodegenerative disor-
der. Alzheimer’s disease (AD) is characterised by the extracellular 
accumulation of the neurotoxic amyloid-β peptide51. Zinc promotes 
the aggregation of amyloid-β into toxic oligomeric forms52. In an 
AD mouse model, synaptic zinc was shown to increase insoluble 
amyloid-β and its deposition in plaques53. Synaptic zinc favours the 
attachment of amyloid-β oligomers to the N-methyl-D-aspartate 
receptor, mediating their excitotoxicity54, and PrPC itself is a high-
affinity receptor for amyloid-β oligomers55. Thus, the reduction in 
PrPC in the brain in AD56 would result in decreased zinc uptake, 
thereby increasing zinc in the synaptic cleft, which in turn would 
promote amyloid-β aggregation and synaptic targeting, potentially 
contributing to the neurodegeneration in AD.
In conclusion, using zinc-specific fluorescent dyes and selective 
receptor antagonists, we have shown for the first time that PrPC 
enhances the uptake of zinc into neuronal cells through AMPA 
receptors, with a subsequent downstream effect on the activity of 
intracellular protein tyrosine phosphatases. The octapeptide repeats 
in PrPC are critical for this zinc uptake, and PrPC interacts with 
both GluA1 and GluA2 subunits of AMPA receptors through its 
N-terminal polybasic region. In addition, in cells expressing mutants 
of PrPC associated with human prion diseases or in scrapie-infected 
cells, this PrPC-mediated zinc uptake is lost, raising the possibility 
that loss of this function may in part contribute to the pathogenesis 
of prion disorders and other neurodegenerative diseases. Thus, we 
have provided the molecular framework underpinning the mecha-
nism by which PrPC is involved in neuronal zinc uptake, and have 
introduced a new facet to prion biology.
Methods
Cell culture and construction of prion protein mutants. Cell culture, prepara-
tion of rat primary hippocampal neurons and construction of PrPC mutants is 
described in Supplementary Methods. Zinc was routinely administered to the cells 
as ZnCl2 in the presence of 10% FCS to provide appropriate physiological ligands 
(albumin and histidine) for the zinc to complex to. When the cells had reached 
confluency, they were collected into PBS (1.5 mM KH2PO4, 2.7 mM Na2HPO4, 
150 mM NaCl, pH 7.4), pelleted and resuspended in lysis buffer (10 mM Tris/HCl, 
pH 7.8, 0.5% (w/v) sodium deoxycholate, 0.5% (v/v) Nonidet P-40, 100 mM NaCl, 
10 mM EDTA, supplemented with complete protease inhibitor cocktail (Sigma, 
P8340)). The protein content of each lysate was determined using bicinchoninic 
acid with BSA as standard.
Measurement of zinc uptake using Zinpyr-1 or Newport Green. Cells were 
cultured overnight in 10% FCS-containing DMEM. For staining with Zinpyr-1, 
following adherence, the cells were exposed to 10% FCS-containing media sup-
plemented with ZnCl2. The media was removed, the cells were washed three  
times with PBS (containing Ca2 +  and Mg2 + ) before 10 µM Zinpyr-1 (a gift from 
Dr A. Favier, Université Joseph Fourier, Grenoble, France) in 50 mM PIPES, 
100 mM KCl, pH 7, was delivered to the cells for 30 min at 37 °C. The cells were 
washed a further three times with PBS (containing Ca2 +  and Mg2 + ), then 50 mM 
PIPES, 100 mM KCl, pH 7, was added and the Zinpyr-1 fluorescence measured  
on a Synergy HT (Bio-Tek; 480 nm excitation and 530 nm emission wavelengths). 
At the end of the time period, the cells were fixed in 70% ethanol at room tem-
perature for 5 min and the adherent monolayers stained with the DNA-binding 
fluorochrome Hoescht 33342 (8.8 µM). Once dry, the fluorescence was measured 
(350 nm excitation and 450 nm emission wavelengths) to determine the cell 
number and enable standardisation of the Zinpyr-1 fluorescence. For staining  
with Newport Green, the cells were loaded with 5 µM Newport Green (Invitrogen, 
Paisley, UK) delivered in 10% FCS media. After 30 min, the dye was replaced  
with 10% FCS-containing media supplemented with ZnCl2. The fluorescence  
was immediately measured (480 nm excitation and 530 nm emission wavelengths) 
for up to 30 min. Finally, the cells were fixed in 70% ethanol and stained with  
Hoescht 33342 as described above. Where indicated, the AMPA receptor antago-
nists CNQX (Ascent Scientific, Bristol, UK), IEM-1460 (Sigma) or sodium pento-
barbital (Euthatal, Marial Animal Health Ltd, Harlow, Essex, UK) were included  
in the incubations. To determine whether PrPC promoted intracellular zinc  
retention, cells were pre-loaded with 32 µM ZnCl2 in 10% FCS-containing  
medium for 1 h. Newport Green (5 µM) was added for a further 30 min to label  
the zinc taken up into the cells. At the end of this incubation, the medium was  
removed, fresh 10% FCS medium added and the level of fluorescence within the 
cells immediately quantified. For each time point over the course of the experi-
ment, the old medium was removed and fresh medium applied before measure-
ment to ensure that any fluorescence measured was derived from the cells and not 
the associated medium. As before, the cells were fixed in 70% ethanol and stained 
with Hoescht 33342 as described above.
SDS–PAGE and western blot analysis. Samples (containing 15 µg of total protein)  
or immunoprecipitates were resolved by electrophoresis through either 14.5  
or 10% polyacrylamide gels31. For western blot analysis, resolved proteins were 
transferred to Hybond-P poly(vinylidene) difluoride membrane (Amersham,  
Little Chalfont, UK). The membrane was blocked by incubation for 1 h with PBS 
containing 0.1% (v/v) Tween 20 and 5% (w/v) dried milk powder. Incubations 
with primary antibodies, including 3F4 and 6D11 (both from Eurogentec Ltd, 
Southampton, UK), SAF32 (Bertin Pharma, France), 6H4 (Celtic Diagnostics, 
Dublin, Eire), 8H4 (Alicon AG, Switzerland) against PrPC, an antibody against 
GluA1 (Abcam, Cambridge, UK) and an antibody against GluA2 (UCDavis/NIH 
NeuroMab Facility), Shadoo (Santa Cruz, CA, USA), DDC39 (anti-Dpl antibody 
was a generous gift from S. Lehmann (Montpellier, France)) and peroxidase- 
conjugated secondary antibodies were performed for 1 h in either the same solu-
tion (for antibody 3F4) or 2% BSA in PBS containing 0.1% (w/v) Tween 20 (for  
all other antibodies). Bound peroxidase conjugates were visualised using an  
enhanced chemiluminescence detection system (Amersham) and recorded  
using Fujifilm LAS-3000. All western blots were repeated a minimum of three 
times.
RNA interference studies. An siRNA specific for murine and rat PrPC or human 
LRP1 (ON-TARGETplus SMART-pool, Dharmacon (Thermo Fisher Scientific 
Biosciences, Northumberland, UK)) or negative control siRNAs (ON-TARGETplus 
Non-Targeting Pool, Dharmacon) were as detailed in ref.28. Cells were washed 
twice with PBS (containing Ca2 +  and Mg2 + ) and a 2 µM SMART-pool siRNA  
solution (Dharmacon) delivered as a complex with DharmaFECT-1 (Dharmacon; 
for SH-SY5Y and N2a cells) or DharmaFECT-3 (Dharmacon; for rat primary  
hippocampal neurons) transfection reagent in serum-free media. After 5 h, the 
serum-free media were replaced with 10% FCS-containing DMEM and the  
cells left for 48 h, and then either lysed for western blot analysis or stained  
with Newport Green.
Co-immunoprecipitation. Brain tissue from 75-day-old wild-type or PrP − / −  
129/P2 mice was homogenised under ice-cold conditions for 10 s in 50 mM 
Tris/HCl, 2 mM EDTA, 150 mM NaCl, 1% (w/v) CHAPSO, pH 7.5. The P101L 
mice were 29 days old57, D177N(M128) mice were 30–54 days old and the 
D177N(V128) mice were 36 days old58. All samples were pre-cleared using (0.25% 
w/v) protein A or protein G Sepharose for 30 min at room temperature. The  
Sepharose was pelleted and the supernatant incubated with the relevant antibody 
(6H4 for PrP, GluA1, GluA2 and control rabbit anti-mouse IgG, or no antibody  
for the bead-only control) overnight at 4 °C. The antibody–antigen complexes  
were pelleted using either protein A or protein G Sepharose (0.5% w/v) for 1 h at 
room temperature and washed with 10 mM KOAc, 1.5 mM MgCl2, 75 mM sodium 
citrate, pH 6.4. The immunoprecipitates were then analysed by western blotting. 
For the chelation studies, 20 µM TPEN was included in all buffers, and washes  
used in the protocol once homogenisation had occurred.
Fluorescence microscopy. Cells were seeded onto coverslips and grown to 50% 
confluence. The cells were pre-loaded with Newport Green for 30 min before 
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exposure to Zn2 +  for an additional 30 min. Cells were then fixed with 4% (v/v) 
paraformaldehyde in PBS for 15 min. PrPC was detected using antibody 3F4 with 
AlexaFlour 594 donkey anti-mouse secondary antibody (Invitrogen, Scotland). 
Nuclear counterstaining was performed using Hoescht 33342 for 5 min before 
mounting on slides using Fluoromount-G (SouthernBiotech) mounting medium. 
For primary neurons, cells were fixed in 4% (v/v) paraformaldehyde in PBS for 
10 min, and then permeabilised with 0.1% Triton X-100 for 20 min. PrPC was  
detected using antibody 6H4 (Prionics AG, Switzerland) with AlexaFlour 488  
donkey anti-mouse secondary antibody (Invitrogen). Individual cells were  
visualised using a DeltaVision Optical Restoration Microscopy System (Applied 
Precision Inc., USA). Data were collected from 30- to 40 0.1-µm thick optical 
sections, and three-dimensional data sets were deconvolved using the softWoRx 
programme (Applied Precision Inc.). The presented images represent individual 
Z-slices corresponding to the middle of the cell.
Surface biotinylation and zinc-stimulated endocytosis of PrPC. Cells were 
incubated for 1 h at 4 °C with 0.5 mg ml − 1 Biotin sulfo-NHS (Sigma-Aldrich). 
Immunoprecipitation of biotin-labelled GluA1 was carried out to determine the 
surface expression of GluA1. Alternatively, following surface biotinylation, cell 
monolayers were incubated at 37 °C in the presence of Zn, with 20 µg ml − 1 RAP 
or LRP1 siRNA as inhibitors of endocytosis28, and then treated with trypsin to 
remove any biotinylated PrPC remaining at the cell surface, with any internalised 
PrPC being protected from digestion.
Measurement of tyrosine phosphatase activity. Confluent cell monolayers  
were collected into PBS. Samples were then pelleted and resuspended in lysis  
buffer (20 mM Tris/HCl, 150 mM NaCl, 1% (v/v) Nonidet-P40, pH 7.4) supple-
mented with complete protease inhibitor cocktail (Sigma, P8340). Whole-brain 
homogenate (120 mg ml − 1 wet weight in PBS, 0.5% NP-40 (v/v), 0.5% sodium 
deoxycholate (v/v) and protease cocktail inhibitor (Roche Diagnostics GMbH,  
Germany)) was prepared from 40-week-old wild-type 129/P2 and 129/P2 PrP − / −  
mice under ice-cold conditions, followed by centrifugation at 100,000 g for 1 h at 
4 °C. The resulting supernatant was collected and analysed for enzyme activity. 
The cell lysates and whole-brain homogenate were analysed using the Tyrosine 
Phosphatase Assay System (Promega, V2471) according to the manufacturer’s 
instructions.
Statistical analysis. All cell analyses were subject to Kruskal–Wallis non-parametric  
one-way analysis of variance, with analyses of the Newport Green kinetic data  
being carried out on the terminal fluorescence value for each measurement  
within the triplicate data set. The brain sample data were analysed by parametric 
independent Student’s t-test. 
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